![](https://monteverdelaw.com/wp-content/uploads/case-logo/armo-biosciences-inc.jpg)
We are investigating ARMO BioSciences, Inc. (“ARMO” or the “Company”) (NasdaqGS: ARMO) relating to the sale of the Company to Eli Lilly and Company. As a result of the sale, ARMO shareholders are only anticipated to receive $50.00 in cash for each share of ARMO.